Background and Aims: Intermittent hypoxia (IH), one of the important pathophysiological components in sleep apnea, has been reported to increase blood glucose levels (BG) in animals (e.g., Obesity 2011;19:2167), although such findings have not consistently emerged across investigational groups. In addition, obstructive sleep apnea syndrome (OSAS) has been reported to be independently associated with insulin resistance (Am J Respir Crit Care Med 2002;165:670). To better understand the glycemic effect of IH, we evaluated the effect of two modalities of IH on BG levels in mice.
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Methods: We exposed C57BL/6J male mice (4-5 week old) to either 12 h/day of mild IH (IHM, alternating F I O 2 -10-11% and normoxia (F I O 2 -21%) with 640 s total cycle duration, or 12 h/day of severe IH (IHS, alternating F I O 2 -6-7% and normoxia, 180 s cycle duration) or sham IH (SIH) every day for 8 weeks (n = 7/group, respectively). After IH (or SIM) exposures, all mice were kept under usual normoxic conditions for 5 weeks and BG levels were measured at around 7 PM.
Results: BG of SIH controls were 222 AE 23 mg/dl, while in IHM the BG concentrations were 186 AE 21 mg/dl and were significantly lower than SIH (P = 0.024). Similarly, BG levels of IHS were 190 AE 36 mg/dl and were also significantly lower than the levels found in SIH-exposed mice (P = 0.041). Results: Gene expression levels of miR-21-5p (adjusted P = 0.024) and miR-23-3p (adjusted P = 0.028) were significantly decreased in treatment-naïve OSA patients as compared with that in PS subjects, while TNF-α gene expression (adjusted P = 0.04) was significantly increased. Gene expression levels of both miR-21-5p, and miR-23-3p were negatively correlated with apnea hypopnea index (r = −.478, P < 0.001; r = −.446, P = 0.001) and oxygen desaturation index (r = −.45, P = 0.001; r = −.421, P = 0.001), while TNF-α gene expression was positively correlated with apnea hypopnea index (r = 0.388, P = 0.003). in vitro IHR treatment result in a significant decrease of miR-21-5p, miR-23-3p, and miR-155-5p gene expressions as compared with normoxic condition, but a significant increase of miR-146b-5p, TLR2, TLR6, TNF-α, HIF-1α, and HIF-2α gene expressions (all P values < 0.05). Both miR-21 5p and miR-23-3p gene expressions were negatively correlated with gene expressions of TLR2, TNF-α, and HIF-2α, and positively correlated with miR-155-5p gene expression. MiR-146a-5p gene expression was positively correlated with both TLR6 and HIF-1α gene expressions.
Conclusion:
MiR-21-5p and miR-23-3p were down-regulated both in severe OSA patients and with in vitro IHR stimuli, while TNF-α was upregulated. These findings provide biological insight into mechanisms by which IHR-suppressed miRs potentiate cell apoptosis and inflammation, and indicate that overexpression of the miR-21/miR-23 could represent a potential therapy for OSA.
